GlassScriptPhysician profile
Alla Tsirlina
NPI 1962423020
$17,309.51
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,002 · 2020: $2,322 · 2021: $3,695 · 2022: $4,485 · 2023: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,363.51 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $3,111.21 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $2,211.93 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $999.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $890.53 | 2019-2023 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $828.37 | 2019-2023 | Xifaxan, Trulance |
| Allergan, INC. | $794.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $714.45 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.33 | 2019-2022 | |
| Lilly USA, LLC | $395.03 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $390.67 | 2019-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $346.40 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $342.61 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $329.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $304.71 | 2020-2023 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $302.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.79 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $240.61 | 2019-2021 | |
| Axsome Therapeutics, INC. | $213.18 | 2023 | Auvelity |
| Nestle Healthcare Nutrition INC. | $206.96 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $192.99 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $124.80 | 2019 | |
| Merck Sharp & Dohme LLC | $115.92 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $93.17 | 2023 | Adthyza, Horizant, Edarbi |
| Ironwood Pharmaceuticals, INC | $68.79 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Tsirlina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.